WallStSmart

Chemed Corp (CHE)vsDaVita HealthCare Partners Inc (DVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 445% more annual revenue ($13.84B vs $2.54B). CHE leads profitability with a 10.2% profit margin vs 5.7%. DVA appears more attractively valued with a PEG of 0.65. DVA earns a higher WallStSmart Score of 70/100 (B-).

CHE

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: 5.69

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CHE.

DVASignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$123.34

Current Price

$192.16

$68.82 premium

UndervaluedFair: $123.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CHE3 strengths · Avg: 9.7/10
Return on EquityProfitability
30.6%10/10

Every $100 of equity generates 31 in profit

Altman Z-ScoreHealth
5.6910/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.658/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

Areas to Watch

CHE4 concerns · Avg: 3.3/10
PEG RatioValuation
1.744/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-0.4%2/10

Earnings declined 0.4%

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CHE

The strongest argument for CHE centers on Return on Equity, Altman Z-Score, Debt/Equity.

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bear Case : CHE

The primary concerns for CHE are PEG Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

DVA carries more volatility with a beta of 0.91 — expect wider price swings.

DVA is growing revenue faster at 6.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chemed Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.

Visit Website →

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?